Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

4.15EUR
29 Mar 2017
Change (% chg)

€0.00 (+0.00%)
Prev Close
€4.15
Open
€4.15
Day's High
€4.15
Day's Low
€4.15
Volume
0
Avg. Vol
27,807
52-wk High
€4.87
52-wk Low
€2.14

Latest Key Developments (Source: Significant Developments)

Biofrontera reports detailed phase III results for Ameluz
Monday, 13 Mar 2017 04:00am EDT 

Biofrontera AG : Reports detailed phase III results for Ameluz in combination with daylight-PDT . Data show daylight photodynamic therapy (PDT) with Ameluz provided excellent results for primary and all secondary study endpoints .EMA filing for EU approval of daylight PDT for actinic keratosis (AK) expected in Q2 2017.  Full Article

Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)
Tuesday, 7 Feb 2017 02:03am EST 

Biofrontera AG : Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT) .Results will be employed for the filing of the EU label extension, which Biofrontera plans to submit in the second quarter of 2017.  Full Article

Biofrontera: EMA recommends indication expansion of ameluz for treatment of basal cell carcinoma
Tuesday, 20 Dec 2016 10:30am EST 

Biofrontera AG : European Medicines Agency recommends indication expansion of ameluz for treatment of basal cell carcinoma .Approval by European Commission expected in next few weeks.  Full Article

Biofrontera 9-month sales up 9 pct at 2.881 mln euros
Wednesday, 30 Nov 2016 02:08am EST 

Biofrontera AG : Sales increased 9 pct to 2.881 million euros for first nine months 2016 compared to 2.635 million euros in same period 2015 . Guidance for full year remains unchanged .Net income loss before taxes was (7.164) million euros for first nine months of 2016, as compared to (9.286) million euros for same period in previous year.  Full Article

Biofrontera: capital increase 5,012,950 new shares fully placed
Thursday, 17 Nov 2016 05:27am EST 

Biofrontera AG :Capital increase: 5,012,950 new shares fully placed.  Full Article

Biofrontera resolves on capital increase and issue of convertible bonds
Tuesday, 1 Nov 2016 02:29am EDT 

Biofrontera AG : Said on Monday resolves on capital increase and issue of convertible bonds . To increase the registered capital of the Company from currently 30,347,813 euros by up to 5,012,950 euros ($5.50 million) to up to 35,360,763 euros by issuing up to 5,012,950 new no-par registered shares with a calculatory participation in the registered capital of 1.00 euro . To issue up to 49,990 subordinate convertible bonds with a nominal amount of 100 euros each and in a total nominal amount of 4,999,000 euros . Bonds mature on Dec. 31, 2020 . Each Bond may be converted into ordinary shares of the Company at a calculatory participation in the registered capital of 1.00 euro and dividend rights from the year of the issue . The conversion price of bonds will initially be 3.00 euros per share, from Jan. 1, 2017 4.00 euros per share and from Jan. 1, 2018 5.00 euros per share .Intends to use the expected net proceeds of approx. 19.5 million euros for the repayment of the bond due on Jan. 1, 2017 in an amount of about 9 million euros, as well as to finance the commercialization of Ameluz in the USA and covering ongoing costs of operations.  Full Article

Biofrontera H1 sales up 9 pct at 1.709 million euros
Wednesday, 31 Aug 2016 02:00am EDT 

Biofrontera AG : Sales increased 9 pct to 1.709 million euros ($1.90 million)in H1 2016 compared to 1.568 million euros in H1 2015 . Net income loss was 3.472 million euros in H1 2016 compared to 7.323 million euros in H1 2015 .Cash on balance sheet was 10.2 million euros as of June 30.  Full Article

Biofrontera accelerates production of BF-Rhodoled lamps to prepare for U.S. commercial launch
Friday, 26 Aug 2016 05:00am EDT 

Biofrontera AG : Accelerates production of BF-Rhodoled lamps to prepare for U.S. commercial launch .First shipment from Biofrontera's own manufacturing site to U.S..  Full Article

Biofrontera gets favourable CHMP assessment for field-directed therapy
Thursday, 28 Jul 2016 03:30am EDT 

Biofrontera AG : Receives favourable CHMP assessment for field-directed therapy and files BCC application . European Commission will issue formal approval in coming weeks . Expands market opportunity for Ameluz beyond actinic keratosis lesions (AK) to field cancerization .Submitted additional label extension application for treatment of basal cell carcinoma (BCC).  Full Article

Biofrontera and Maruho initiate joint project to explore development opportunities
Wednesday, 13 Jul 2016 07:00am EDT 

Biofrontera AG :Biofrontera AG and Maruho initiate joint project to explore development opportunities.  Full Article

More From Around the Web

BRIEF-Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)

* Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT)